<DOC>
	<DOCNO>NCT01014052</DOCNO>
	<brief_summary>The purpose study : - evaluate safety oral QLT091001 - evaluate whether 7-day treatment oral QLT091001 improve visual function subject LCA RP due RPE65 LRAT mutation - evaluate duration visual function improvement ( observe )</brief_summary>
	<brief_title>Safety/Proof Concept Study Oral QLT091001 Subjects With Leber Congenital Amaurosis ( LCA ) Retinitis Pigmentosa ( RP ) Due Retinal Pigment Epithelial 65 Protein ( RPE65 ) Lecithin : Retinol Acyltransferase ( LRAT ) Mutations</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<criteria>Subjects diagnose LCA RP ( mutation either RPE65 LRAT ) Subjects LCA must 565 year age Subjects RP must 1865 year age Subjects `` bestcorrected '' visual acuity 3 letter well ( 20/800 Snellen equivalent ) viable photoreceptors OCT/FAF . Subjects actively participate experimental therapy study receive experimental therapy within 60 day Day 0 . Subjects clinically important abnormal physical finding Screening . Subjects take prescription investigational oral retinoid medication ( e.g. , Accutane , ® Soriatane® ) within 6 month Day 0 subject tolerate previous oral retinoid medication exclude regardless time last exposure . Subjects history diabetes chronic hyperlipidemia , hepatitis , pancreatitis , cirrhosis . Subjects take supplement contain ≥10,000 IU vitamin A within 60 day screen</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>